A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...

We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...

2021年，O药成为全球首个获批与化疗联合一线治疗晚期胃癌的PD-1抑制剂；2023年K药也获批这一适应症。然而在事后的检查中， FDA发现这些药物对于PD-L1阴性患者“似乎不太有利” ，所以才考虑给PD-1药物治疗胃癌增加限制条件。

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...

The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...

在这项探索 PM8002/BNT327 联合化疗在 EGFR 突变非小细胞肺癌患者的安全性和有效性的 II 期研究中，研究者入组了接受 EGFR-TKI 治疗后出现疾病进展的 EGFR 突变 NSCLC。这些患者接受 PM8002/BNT327 ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

中国临床肿瘤学会 胃癌 ...

A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...